AGEX THERAPEUTICS INC (AGE)       0.59  +0.02 (+2.61%)

0.59  +0.02 (+2.61%)

US00848H1086 - Common Stock

AGEX THERAPEUTICS INC0.59

NYSEARCA:AGE (12/9/2022, 7:25:04 PM)+0.02 (+2.61%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-10 2022-11-10/amc Earnings (Next) 03-27 2023-03-27
Ins Owners 0.12% Inst Owners 12.51%
Market Cap 22.39M Shares 37.95M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts N/A
IPO 11-29 2018-11-29

Stock Screener Links

Screen Image

American Stock Exchange Stock Screener

Find more stocks on American Stock Exchange

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AGE Daily chart

Company Profile

AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. The company is headquartered in Alameda, California and currently employs 5 full-time employees. The company went IPO on 2018-11-29. The firm's product pipeline includes two cell-based therapies, which is derived from telomerase-positive pluripotent stem cells (PSCs) and two product candidates, which is derived from its induced Tissue Regeneration (iTRTM) technology. The firm's AGEX-BAT1 is being developed for the treatment of certain age-related metabolic disorders, such as Type II (adult-onset) diabetes. Its AGEX-VASC1 is designed to restore vascular support in aged ischemic tissues, such as the aging heart. The firm's iTRTM technology product candidates include AGEX-iTR1547, which is a drug-based formulation, and AGEX-iTR1550 (Renelon), which is a gene delivery technology.

Company Info

AGEX THERAPEUTICS INC

1101 Marina Village Parkway, Suite 201

Alameda CALIFORNIA 94501

P: 15106718370.0

CEO: Michael D. West

Employees: 5

Website: http://www.agexinc.com

AGE Twits

Here you can normally see the latest stock twits on AGE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example